SellYourAIData
Get a free valuation Contact

AI Data Deal TrackerDeal brief

×

Tempus discloses GSK agreement with $180M minimum spend that includes licensed data

Tempus AI's annual filing says GSK committed to spend at least $180 million, of which $70 million was paid on execution, on Tempus products and services including licensed data, under a 2022 agreement amended in May 2024. GSK can trigger up to $120 million more for 2028 to 2030.

CHICAGO, February 2025 Tempus AI disclosed in its annual report on Form 10-K that GSK has committed to spend a minimum of $180 million on Tempus products and services, which include licensed data, under an agreement first signed in August 2022 and amended in May 2024.1 The exact day of the amendment is not given in the filing text we read, so the date on this entry is approximate.

Terms of the deal

The filing says that, on a non-exclusive basis, Tempus provides GSK with certain products and services including licensed data, sequencing, clinical trial matching, organoid modeling services, algorithm development and others.1 In exchange for certain discounted prices, GSK committed to spend a minimum of $180 million, of which $70 million was paid upon execution.1

The agreement continues through December 31, 2027 unless terminated sooner. An additional commitment of up to $120 million may be triggered at GSK's election for the years 2028, 2029 and 2030.1

What it means for data sellers

The filing shows how a large buyer structures a long data relationship: an upfront payment, a minimum spend and an option for later years. The amount is shared across data and services, so it should not be read as a per-record or per-dataset price. This is a pharma data and services contract, not an AI-training license.

This entry is a news summary. SellYourAIData was not involved in the deal.

How the deal came together

  1. Agreement signed in 2022. Tempus entered a Strategic Collaboration Agreement with GSK in August 2022, which was amended in May 2024.
  2. Data is one of several products. On a non-exclusive basis Tempus provides GSK products and services including licensed data, sequencing, clinical trial matching, organoid modeling services and algorithm development.
  3. A spending commitment. In exchange for certain discounted prices, GSK committed to spend a minimum of $180 million, of which $70 million was paid upon execution.
  4. Term and option. The term runs through December 31, 2027, and an additional commitment of up to $120 million may be triggered at GSK's election for 2028, 2029 and 2030.

Takeaways for companies with data

  • Pharma buyers commit large minimum spends in exchange for volume discounts, and data licensing is one line item in a bundle.
  • An upfront payment of about 39% of the minimum ($70M of $180M) gives the seller cash early and locks in demand.
  • The $180M figure covers all products and services, so it is not a price for the data alone.

Sources

Every numbered reference above points to an entry here. Figures come from these pages as of the date shown at the top of the article. Where a source reports a number it got from unnamed people, the text says so.

  1. Tempus AI, Inc. Form 10-K for fiscal year 2024 (U.S. SEC filing, February 2025)

###

About the AI Data Deal Tracker

SellYourAIData tracks publicly reported sales and licenses of data to AI companies, with the price, terms and sources for each. Entries are checked against public reporting and updated as deals change. SellYourAIData was not involved in this deal. To ask what your company's data could sell for, get a free valuation. To report a deal, contact us.